csr at novartis

CSR at Novartis

Something about Leprosy…

• Today only 4 countries face the prevalence of leprosy exceeding one case per 10,000 inhabitants, compared to 122 countries in 1985.

• A reduction of almost 98% of leprosy cases reported worldwide in 2007 (compared to 1985) to 225,000.

• 2 of the 3 drugs used in MDT were developed by Novartis in their research laboratories.

MDT

• Nearly all the global supply of MDT is provided by a collaboration between the WHO and Novartis to cover the period 2000-2005.

• Novartis donations helped cure more than 14 million patients since 1985.

• Since 2000, Novartis has supplied 41 million blister packs of NDT.

Patients

• Patients first

• Free product valued at $169 million to 109,000 patients

• Free leprosy and tuberculosis treatment and offer the antimalarial drug Coartem without profit through multilateral institutions and public-private partnerships.

• Novartis has registered the East Village buildings and parking garage for LEED (Leadership in Energy and Environmental Design) certification.

• LEED is the nationally accepted benchmark for the design, construction and operation of high performance green buildings, developed by the U.S. Green Building Council,

Registering the Benchmark

Environmental Care

• Energy efficient roof.• Recycling waste.• Clean renewable sources of energy.• CFLs• Hybrid Vehicles• Solar Array (produces 140,000 KW

annually )• Using Light Sensors

References

• http://www.novartis.com/

• http://www.who.int/lep/partners/novartis/en/index.html

Thank You